Human Microbiome Market is Expanding at a CAGR of 9.80% by 2024

The global human microbiome market could be divided into two chief classifications: therapeutics and diagnostics. Analysts at TMR have envisaged the global human microbiome therapeutics market to expand its growth at a 9.2% CAGR during the forecast tenure 2020-2024. By 2024, the market could earn an around US$1.7 bn after touching a valuation of US$1.2 bn in 2020. On the basis of technology, the analysts have foreseen the global human microbiome diagnostics market to testify of the marginal lead expected to be secured by 16s rRNA sequencing at a 2024 valuation of US$0.7 bn. Regionally, North America could be at a commanding position in the global human microbiome therapeutics market while growing at a CAGR of 9.1% between 2020 and 2024.

Read Report Overview: https://www.transparencymarketresearch.com/human-microbiome-market.html

Rising Partnerships between Industry and Institutes Fuel Growth in Market

Earlier in 2017, there were clinical translational medicine collaborations between Vedanta Biosciences and two institutes, i.e. Leiden University Medical Center and Stanford University School of Medicine. With a view to improve their market strategies, companies are looking to team up with eminent physicians, researchers, and scientists in the field. If you are a small startup or your company needs angel investors and venture capitalists, it could be encouraging to know that the world human microbiome market has witnessed a rise in venture capital investments in the recent years. Microbiome-based diagnosis and treatment methods have been showing quite some promise, thus winning the confidence of investors in the market.

The completion of the NIH Human Microbiome Project has propelled growth in the market as it has provided advanced knowledge about the relation between human health and the microbiome. This knowledge is extensively used in drug discovery and development.

Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3999

Clinical Trial Setbacks and Regulatory Hurdles Cause Problems in Growth

Undesirable results obtained out of clinical trials and regulatory hurdles have been projected to upset the growth of the international human microbiome market when it is still in the nascent phase. However, advances and expertise in the field could dilute the effect of such minor setbacks companies may have been facing today. Concerns over anonymity and privacy of the genetic data of subjects similar to those related to 23andMe’s genetic tests could be another factor restraining market growth.

Since microbiome composition changes over time and holds a dynamic nature and the microbiome of every individual is different, standardization of diagnostic tests is extremely crucial. If the standardization is not actuated well, there could be a possibility of market growth being hampered. However, improved success rates of the treatment of major health problems and life-threatening diseases using microbiome-based techniques have been prophesied to set the tone for a valuable growth in the international human microbiome market. Furthermore, novel drug delivery systems and drug formulations could create robust growth opportunities in the market.

Download Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3999

The global human microbiome market has been studied by Transparency Market Research (TMR) to attract a substantial count of companies foraying into it. This could take place in a time where the market is still growing out of its nascent stage. TMR has also predicted the market to witness an intense competition, as a result, in the near future. The market has been occupied by leading contestants such as uBiome Inc., Synthetic Biologics Inc., Seres Therapeutics, Vedanta Biosciences, and Enterome Biosciences SA. If you are a player looking to expand your business in the market, you could follow some of the go-to strategies adopted by key companies such as mergers and acquisitions.

Request For Discount On This Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=3999

Human Microbiome Market is expected to cross the mark of US3.2 bn up to 2024

Global Human Microbiome Market: Snapshot

With ample unmet needs, the global market for human microbiome exhibits high potential of growth. The market is set to emerge as a lucrative business in the near future, thanks to the increasing emphasis on diagnosis and treatment of various underrated diseases. The worldwide human microbiome market will be US$2.2 bn in 2020. The lack of targeted drugs for specific conditions, such as ulcerative colitis and C.difficile infection across the world makes this market highly opportune for players to set their innovative drug ideas on the path to commercial success. Driven by these factors, the opportunity in this market is slated to rise at a CAGR of 9.80% between 2020 and 2024 and reach US$3.2 bn by the end of 2024.

This 176 page report gives readers a comprehensive overview of the human microbiome market. Browse through 31 data tables and 87 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/human-microbiome-market.html

Microbiome diagnostics and microbiome therapeutics are the two prominent sections of the global human microbiome market. Currently, the market is in the budding phase, with most of the therapies still being in preclinical or clinical (phase I or phase II) stage. The diagnosis technology is also in the development phase and the leading companies have begun to allocate funds for the research and development and the management of clinical studies for their innovative class of therapies. All these factors are likely to propel this market significantly over the next few years. The human microbiome therapeutics market is likely to report a CAGR of 9.20% during the period of 2020 to 2024, whereas the market for human microbiome diagnostics is anticipated to rise at an 8.60% CAGR between 2018 and 2024.

North America to Report Continued Leadership

North America, Asia Pacific, the Middle East and Africa, Europe, and Latin America are the key regional markets for human microbiome across the world. Thanks to the presence of a state-of-art medical and healthcare industry and early adoption of technology, North America has occupied the top position in the global market. Researchers expect that the rising number of venture-capital funded start-ups and the increasing investments by leading players for research and development of drugs will support the North America market for human microbiome over the forthcoming years, ensuring its dominance. The human microbiome therapeutics market in North America is anticipated to report a rise at a CAGR of 9.10% between 2020 and 2024 while the region’s human microbiome diagnostics market will progress at an 8.80% CAGR from 2018 to 2024.

Europe, which acquired the second position in the global human microbiome market, is projected to maintain its position over the years to come. The U.K. and France have emerged as the key domestic markets for human microbiome in Europe. The high investments by companies in this domain are expected to boost both these domestic markets in the next few years. Apart from this, countries, such as Sweden and the Netherlands, are also anticipated to contribute well to the Europe market for human microbiome market in the near future.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving human microbiome market during 2018 - 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3999

Metagenomic Sequencing to Outpace 16s rRNA in Future

On the basis of technology, the global market for human microbiome is classified into 16s rRNA sequencing and metagenomic sequencing. Both the technology are equally popular platforms for detection in the microbiome-based diagnostics. However, the metagenomic sequencing segment is likely to surpass the 16s rRNA segment over the next few years, albeit by a small margin, as a large number of companies are opting for the diagnosis of a more comprehensive microbiome profile.

At the forefront of the global market for human microbiome are Vedanta Biosciences, Synthetic Biologics Inc., Seres Therapeutics, Second Genome, uBiome Inc., Rebiotix Inc., Osel Inc., MicroBiome Therapeutics LLC., Metabiomics Corp., Enterome Biosciences SA, and AO Biome LLC. Some of the other prominent participants in this market are Metabogen AB, Becton Dickinson & Co., Evelo Biosciences, ARTPred, MaaT Pharma, Blue Turtle Bio Technologies, Axial Therapeutics, Whole Biome, 4D Pharma, Symbiotix Therapies, Phi Therapeutics, Synlogic, and Biospherex LLC. 

Human Microbiome Market 2024: Business Development Analysis

The global human microbiome market is in a nascent phase, which is attracting a large number of players to foray into this market. Transparency Market Research (TMR) estimates that this, resultantly, is likely to intensify the competition within this market over the coming years. Enterome Biosciences SA, Vedanta Biosciences, Seres Therapeutics, Synthetic Biologics Inc., uBiome Inc., Second Genome, Osel Inc., Rebiotix Inc., Metabiomics Corp., MicroBiome Therapeutics LLC., and AO Biome LLC are among the frontrunners in the arena.

The leading players are focusing towards product innovations and technological advancements to consolidate their position in the global human microbiome market in the near future. “Mergers and acquisition will be other go-to strategies preferred by market participants in order to expand their business,” says the author of the report.

This 176 page report gives readers a comprehensive overview of the human microbiome market. Browse through 31 data tables and 87 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/human-microbiome-market.html

The global market for human microbiome is poised to expand at a noteworthy CAGR of 9.80% between 2020 and 2024, reaching a valuation of US$2.2 bn by 2020. By the end of forecast period, the market is expected to cross the mark of US3.2 bn.

North America to Stay at Forefront of Growth until 2024

Therapeutics and diagnostics are the two primary categories of the global human microbiome market. The market for human microbiome therapeutics is estimated to register a higher CAGR of 9.20% during the forecast period. Geographically, North America will continue to account for the lion’s share in the global market until 2024, thanks to the widening base of venture-capital funded startups. The growth of the region can also be attributed to the presence of a state-of-art medical and healthcare sectors and early adoption of technology.

Increasing Clinical Trials for Gut Health-based Diseases to Drive Human Microbiome Market

High unmet needs coupled with the growing investments by venture capital organizations and angel investors in research and development activities in the field of diagnosis and therapeutics of underrated diseases are providing a fillip to the market. With human microbiome being a novel and highly potent realm, drug manufacturers across the globe are increasing their focus on it, which is translating into the greater capital investments. “Human microbiome is used for early detection and diagnosis of diseases. Moreover, it has been accredited as a new target for drug development,” says a TMR analyst. The rising number of clinical trials for gut health-based diseases is also playing a pivotal role in the growth of the global market.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving human microbiome market during 2018 - 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3999

Dearth of Proper Infrastructure and Skilled Personnel for Research to Hamper Growth Prospects

The increasing collaborations between market players and research institutes are shaping the future of the global human microbiome market. However, several factors are acting as dark spots in the landscape. The dearth of personnel with expertise and lack of proper infrastructure for research, especially in developing countries, are impeding the upward climb of the market. Moreover, human microbiome is still in its initial stages and therefore, there are various uncertainties over its performance. Besides this, stringent government regulations for approval are acting as a bottleneck in the development of the market.
The study presented here is based on a report by Transparency Market Research (TMR), titled “Human Microbiome Market (Indication - Gastrointestinal and Metabolic Disorders, Women’s Health, and Cancer; Technology - 16s rRNA Sequencing and Metagenomic Sequencing; Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Women’s Health, and Skin Disorders) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 – 2024.”

Recent Trends in Human Microbiome Market

A study on the global human microbiome market by Transparency Market Research (TMR) reports that the increasing incidence of chronic medical conditions such as diabetes, obesity, cancer, cardiovascular diseases, and neurological disorders is the key driving force behind the growing demand for human microbiome across the world. The report, titled “Human Microbiome Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023,” further states that the rising awareness among people regarding the benefits of microbiome products is also adding to the increasing demand for human microbiome. However, strict government regulations pertaining to the usage of microbiome products may perturb the growth trajectory of this market in the coming years.

On the other hand, the continuing advancement in biomedical sciences is likely to create opportunities for the application of human microbiome over the next few years. The increasing interest of leading players in mergers and acquisitions is expected to propel this market signifcanlty during the forecast period, notes the market study.

In this report, the global market for human microbiome has been studied on the basis of disease, product, application, and region. Geographically, the worldwide market for human microbiome has been segmented into Europe, North America, Asia Pacific and the Rest of the World. North America and Europe have been leading the demand for human microbiome over the recent past and are expected to do so during the forecast period.

The continual improvement in the biotechnological and microbiological research infrastructure has been driving the growth of the human microbiome market in these regions since the last few years. Over the coming years, the mounting risk of lifestyle disorders is likely to propel this market in Europe and North America, states the research report.

View exclusive Global strategic Business Report : http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3999

Based on disease, the report classifies the global market into autoimmune ailments, allergic conditions, diarrhea, obesity, cancer, diabetes, and various other diseases. Based on product, the market has been segmented into probiotics, prebiotics, drugs, devices, and medical foods. Furthermore, the medical food segment has been categorized into oral rehydration products, nutritionally complete formulae, nutritionally incomplete formulae, and formulae for metabolic disorders. Diagnostics and therapeutics have been identified as the two main application areas of human microbiome in this research study.

The leading players in the worldwide human microbiome market are ActoGenix, Enterome Bioscience SA, DuPont, Metabiomics Corp., MicroBiome Therapeutics LLC, Merck & Co. Inc., OptiBiotix Health Plc, Ritter Pharmaceuticals Inc., Osel Inc., Second Genome Inc., ViThera Pharmaceuticals Inc., Vedanta BioScience Inc., and Yakult Honsha Co. Ltd., states the report.